Phosphoramidate ProTides of 2′-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties

Journal of Medicinal Chemistry

Volumn 53, Issue 13, 2010, Pages 4949-4957

  McGuigan, Christopher ^a   Gilles, Arnaud ^a   Madela, Karolina ^a   Aljarah, Mohamed ^a   Holl, Sabrina ^a   Jones, Sarah ^a   Vernachio, John ^b   Hutchins, Jeff ^b   Ames, Brenda ^b   Bryant, K Dawn ^b   Gorovits, Elena ^b   Ganguly, Babita ^b   Hunley, Damound ^b   Hall, Andrea ^b   Kolykhalov, Alexander ^b   Liu, Yule ^b   Muhammad, Jerry ^b   Raja, Nicholas ^b   Walters, Robin ^b   Wang, Jin ^b   Chamberlain, Stanley ^b   Henson, Geoffrey ^b   more..

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Inhibitex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' C METHYLGUANOSINE; ALANINE; AMINO ACID; ESTER; GUANOSINE TRIPHOSPHATE; NUCLEOSIDE; PHOSPHORAMIDIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PHOSPHORYLATION; RAT; REPLICON; SYSTEMIC DISEASE; VIRUS INHIBITION;

ADENOSINE TRIPHOSPHATE; AMIDES; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; FEMALE; GUANOSINE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED ICR; PHOSPHORIC ACIDS; VIRUS REPLICATION;

EID: 77954347956     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1003792     Document Type: Article

References (17)

1. Hoofnagle, J. H.; Seef, L. B. Peginterferon and ribavirin for chronic hepatitis C N. Engl. J. Med. 2006, 355, 2444-2451
2. Soriano, V.; Madejon, A.; Vispo, E.; Labarga, P.; Garcia-Samaniego, J.; Martin-Carbonero, L.; Sheldon, J.; Bottecchia, M.; Tuma, P.; Barreiro, P. Emerging drugs for hepatitis C Expert Opin. Emerging Drugs 2008, 13, 1-19
3. Brown, N. A. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part 1: Nucleoside analogues Expert Opin. Invest. Drugs 2009, 18, 709-725
4. Klumpp, K.; Leveque, V.; Le Pogam, S.; Ma, H.; Jiang, W.-R.; Kang, H.; Granycome, C.; Singer, M.; Laxton, C.; Hang, J. Q.; Sarma, K.; Smith, D. B.; Heindl, D.; Hobbs, C. J.; Merrett, J. H.; Symons, J.; Cammack, N.; Martin, J. A.; Devos, R.; Najera, I. The novel nucleoside analog R1479 (4′- azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture J. Biol. Chem. 2006, 281, 3793-3799
5. Eldrup, A. B.; Prhavc, Ml.; Brooks, J.; Bhat, B.; Prakash, T. P.; Song, Q.; Bera, S.; Bhat, N.; Dande, P.; Cook, P. D.; Bennett, C. F.; Carroll, S. S.; Ball, R. G.; Bosserman, M.; Burlein, C.; Colwell, L. F.; Fay, J. F.; Flores, O. A.; Getty, K.; LaFemina, R. L.; Leone, J.; MacCoss, M.; McMasters, D. R.; Tomassini, J. E.; Langen, D. V.; Wolanski, B.; Olsen, D. B. Structure-Activity Relationship of heterobase modified 2′- C -methyl ribonucleosides as inhibitors of hepatitis C virus RNA replicaton J. Med. Chem. 2004, 47, 5284-5297 (Pubitemid 39314927)
6. Cahard, D.; McGuigan, C.; Balzarini, J. Aryloxy phosphoramidate Triesters as Pro-Tides Mini-Rev. Med. Chem. 2004, 4, 371-382
7. McGuigan, C.; Cahard, D.; Sheeka, H. M.; De Clercq, E.; Balzarini, J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite J. Med. Chem. 1996, 39, 1748-1753
8. McGuigan, C.; Kelleher, M. R.; Perrone, P.; Mulready, S.; Luoni, G.; Daverio, F.; Klumpp, K.; Smith, D. B. The application of phosphoramidate ProTide technology to the potent anti-HCV aompound 4′-azidocytidine Bioorg. Med. Chem. Lett. 2009, 19, 4250-4254
9. McGuigan, C.; Perrone, P.; Madela, K.; Neyts, J. The phosphoramidate ProTide approach greatly enhances the activity of beta-2′- C -methylpurines against Hepatitis C Virus Bioorg. Med. Chem. Lett. 2009, 19, 4316-4320
10. Furman, P. A.; Wang, P. Y.; Niu, C. R.; Bao, D. H.; Symonds, W.; Nagarathnam, D.; Steuer, H. M.; Rachakonda, S.; Ross, B. S.; Otto, M. J.; Sofia, M. PSI-7851: A novel liver-targeting nucleotide prodrug for the treatment of Hepatitis C. Hepatology 2009, 48 (Suppl), presented at 59th Annual Meeting of the American Association for the Study of Liver Diseases, Oct 31-Nov 4, 2008, San Francisco, CA, poster 1901.
11. Birkus, G.; Kutty, N.; He, G.-X.; Mulato, A.; Lee, W.; McDermott, M; Cihlar, T. Activation of GS-7340 and other Tenofovir phosphonoamidate prodrugs by human proteases Antiviral Res. 2007, 74, A57
12. Notably, the agent has recently been resolved into its separate diastereoisomers. See: Chun, B. K.; Rachakonda, S.; Du, J. F.; Khan, N.; Shi, J. X.; Stee, W.; Cleary, D.; Ross, B. S.; Sofia, M. J. An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5BpPolymerase J. Org. Chem. 2009, 74, 6819-6824
13. McGuigan, C.; Sutton, P. W.; Cahard, D.; Turner, K.; OLeary, G.; Wang, Y.; Gumbleton, M.; De Clercq, E.; Balzarini, J. Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T) Antivir. Chem. Chemother. 1998, 9, 473-479
14. Zhou, X. J.; Pietropaolo, K.; Sullivan-Bólyai, J.; Kuca, B.; Liu, W.; Xu, L.; Belanger, B.; Khan, S.; Mayers, D. IDX184, A liver-targeted nucleotide HCV polymerase inhibitor: Results of a first-in-man safety and pharmacokinetic study. Presented at EASL, 25th April 2009, poster no. 966.
15. Derudas, M.; Carta, D.; Brancale, A.; Vanpouille, C.; Lisco, A.; Margolis, L.; Balzarini, J.; McGuigan, C. The application of phosphoramidate ProTide technology to Acyclovir confers anti-HIV inhibition J. Med. Chem. 2009, 52, 5520-5530
16. ClogP values were calculated using ChemOffice Ultra 11.0.
17. McGuigan, C.; Tsang, H. W.; Cahard, D.; Turner, K.; Velazquez, S.; Salgado, A.; Bidois, L.; Naesens, L.; De Clercq, E.; Balzarini, J. Phosphoramidate derivatives of d4T as inhibitiors of HIV: the effect of amino acid variation Antiviral Res. 1997, 35, 195-204